MeiraGTx
MeiraGTx is a biotechnology firm specializing in the development of gene therapies for serious diseases, with a focus on inherited retinal diseases, neurodegenerative diseases, and severe forms of xerostomia.
Services
MeiraGTx specializes in developing gene therapies designed to address and treat serious diseases. Their services involve a vertically integrated platform that encompasses end-to-end manufacturing capabilities. This comprehensive approach enables the company to manage the entire process of gene therapy development, from initial viral vector design and optimization to downstream purification and quality control. Their gene regulation technology allows precise control of gene expression through synthetic riboswitches in mammalian cells, further enhancing their therapeutic offerings.
Focus Areas
MeiraGTx focuses on several critical areas in medical research and therapy. Their primary areas of concentration include inherited retinal diseases, neurodegenerative diseases, and severe forms of xerostomia. The company has six ongoing clinical programs specifically targeting these critical conditions, supported by a broad pipeline of preclinical and research programs. These focus areas are indicative of their commitment to addressing some of the most challenging and underserved medical needs.
Manufacturing Capabilities
MeiraGTx boasts significant manufacturing infrastructure with facilities located in London, UK, and Shannon, Ireland. Combined, these facilities offer over 180,000 square feet of space dedicated to producing gene therapies. The capabilities within these facilities include cell expansion, bulk production of viruses, downstream purification suites, fill and finish processes, and quality control laboratories. These comprehensive capabilities enable MeiraGTx to maintain a consistently high standard of production and quality control throughout the manufacturing process.
Gene Regulation Technology
MeiraGTx's gene regulation platform is a cornerstone of its therapeutic approach. This platform includes synthetic riboswitches that are designed to function within mammalian cells, facilitating precise control of gene expression. These riboswitches are regulated using proprietary oral small molecules, which allow for secure and adjustable modulation of gene activity. This technology has the potential to transform the way gene therapies are developed and administered, making treatments more adaptable and targeted.
Strategic Collaborations
MeiraGTx has engaged in strategic collaborations to further the development and commercialization of its gene therapies. Notably, they have partnered with Janssen Pharmaceuticals, enhancing their capacity to bring innovative therapies to market more effectively. These collaborations are crucial for advancing their clinical programs and ensuring that their gene therapies reach patients who need them.